Original Research

Impact of COVID-19 pandemic on dermatology practices: Results of a web-based, global survey

Shashank Bhargava MD a, Charles McKeever MD b, George Kroumpouzos MD, PhD, FAAD c,d,e,*

a Department of Dermatology, R.D. Gardi Medical College, Ujjain, India
b Department of Dermatology, University of Panama Medical School and Social Security Hospital, Panama City, Panama
c Department of Dermatology, Alpert Medical School, Brown University, Providence, RI, United States
d Department of Dermatology, Medical School of Jundiaí, São Paulo, Brazil
e GK Dermatology, PC, S Weymouth, MA, United States

A R T I C L E   I N F O

Article history:
Received 12 August 2020
Received in revised form 26 September 2020
Accepted 29 September 2020

Keywords:
COVID-19
Dermatology
Practice
Procedures
Teledermatology
Hospital service

A B S T R A C T

The spectrum and magnitude of changes in dermatology practice induced by the COVID-19 pandemic have not been adequately studied.

Objective: This study aimed to assess the immediate and long-term effects of the pandemic on dermatology practice on a large scale, including the clinical activity of participants, frequency and types of procedures used, and telemedicine (TD) use.

Methods: This web-based, global survey included 733 dermatologists. The primary outcomes are percentages of respondents providing in-person consultations, hospital service, and TD and performing procedures. Factors in logistic regression models that may influence the odds ratio (OR) for TD use during pandemic and for future use also were analyzed.

Results: The percentages of respondents providing in-person consultations (46.6% vs. 100% before the pandemic) and hospital service (27% vs. 52.8% before the pandemic) as well as performing procedures (25.6% vs. 100% before the pandemic) decreased, whereas practicing TD increased three-fold (75.2% vs. 26.1% before the pandemic) during the pandemic (p < .001 for each). Practice location was associated with TD use during the pandemic and with its expected use in the future (p < .001 for both), with North American respondents indicating the highest use. TD use during the pandemic showed a positive correlation with TD use before the pandemic, performing procedures and, more specifically, with biopsies of suspicious pigmented lesions during the pandemic (p < .001 for each). TD use before the pandemic was the most powerful predictor of TD use during the pandemic (OR: 16.47; 95% confidence interval, 7.12–38.06). More than two thirds of participants (68.6%) expect to use TD in the future. The factor with the largest increase in OR on the expectation of future TD use was >1000 COVID-19 cases in the country (OR: 3.80; 95% confidence interval, 2.33–6.21).

Conclusion: This survey indicates a profound immediate effect of the pandemic on dermatology practice. The pandemic appears to have substantially contributed to an increased use of TD in the long run.

© 2020 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Background

The COVID-19 pandemic is affecting health care systems across the globe (Emanuel et al., 2020; Mahmood et al., 2020). Dermatology has faced unprecedented challenges, including a reduction in nonessential visits and procedures (Gisondi et al., 2020; Kumar et al., 2020; Wollina, 2020). To contain COVID-19, in-person consultations have been reduced and the implementation of teledermatology (TD) has increased (Fahmy et al., 2020; Litchman and Rigel, 2020; Muddasani et al., 2020). Dermatologists served on the frontline in several parts of the globe (Bhargava et al., 2020c; Zheng et al., 2020) and played an important role in enhancing preventive measures (Goren et al., 2020; Tao et al., 2020; Yan et al., 2020). However, dermatologists face a shortage of personal protective equipment in the health care system (Bhargava et al., 2020a; Goldust et al., 2020a). Although the immediate effects of the pandemic, including a decrease in patient visits and postponing nonessential procedures, have been documented in a few reports (Litchman and Rigel, 2020; Zheng and Lai, 2020), the long-term...
effects have not been assessed. The spectrum and magnitude of changes in dermatology practice during the COVID-19 pandemic also have not been evaluated on a large scale (Temiz et al., 2020).

Objectives

We assessed dermatology practices on a large scale during the pandemic, taking into account practice setting and population density, as well as conditions in each participant’s country (i.e., number of COVID-19 cases and lockdown status). Our study addresses the clinical activity of participants, frequency and types of procedures performed, and TD use. We developed logistic regression models to identify factors that influence the odds ratio (OR) for TD use during the pandemic and for the future.

Methods

Study design

This is a web-based, cross-sectional study.

Survey instrument

Development of the survey went through the stages of item generation, item reduction, formatting, and composition. The questionnaire was then pilot tested in the investigators’ academic dermatology departments to ensure proper flow, salience, and acceptability of the questions. During the pilot phase, we ensured that each question was understood the same way by dermatologists practicing in different continents. Questions relevant to dermatology practice specifics that are common in one geographic area but uncommon in another were eliminated during pilot testing.

Cognitive testing was further evaluated and refinements were made if deemed appropriate. The final instrument included sets of questions on demographics, practice specifics before and during the pandemic, and hospital service. The instrument also included questions relevant to the health care system, training of residents/fellows, and other questions (e.g., mental health status of participants during the pandemic) that are reported separately.

Survey administration

The survey instrument was formatted in Google forms and distributed electronically between April 1 and April 20, 2020 to the investigators’ contacts on social media sites, specifically to board-certified dermatologists. Participants could access the survey via a link that was provided. The survey instrument was disseminated twice, the data collection period was extended, and reminder messages were sent to increase participation. Two questions relevant to the number of biopsies performed and postponed during the pandemic were added to the instrument before the second dissemination. This was an anonymous survey; there was no process of data linkage, and neither recording nor dissemination generated identifiable information.

Variables

The primary outcomes are percentages of respondents providing in-person consultations, hospital service, and TD and performing procedures during the pandemic. Factors in logistic regression models that may influence the OR for TD use during the pandemic and for future use were analyzed.

Statistical analysis

A total of 1120 dermatologists were surveyed, and 746 responded (response rate: 66.6%). Thirteen respondents were excluded because they were not board-certified dermatologists and/or missed essential demographic questions and/or responded to <80% of the questions for which they qualified. This left a sample of 733 respondents for analysis. Frequencies and percentages of respondents in the subgroups within each categorical variable are provided. Numerical data are presented with median and interquartile range (IQR) or mean, as appropriate. Pairs of categorical variables were assessed for association with the $\chi^2$ or McNemar test. A Mann-Whitney (Wilcoxon rank sum) test was used to assess the relationships between two divisions of ordinal variables as defined by a binary covariant. The relationship between the only two continuous variables was characterized by the Spearman correlation coefficient. The threshold of significance for $p$ values was adjusted for multiple comparisons using a false discovery rate (cut-off rate: $p < .05$; Chen et al., 2017).

Logistic regression models were generated for each of the following binary dependent variables: TD use during the pandemic and future TD use. Models were created through forward selection, in which candidate independent variables found to be associated with the outcome variable at $p \leq .0001$ were entered in order from the smallest to larger $p$ values. Once entered into the model, variables with an OR estimated at $p > .05$ were dropped. Nested models were compared using the log likelihood test, and those that were not nested were compared on model specification, Akaike information criterion, Hosmer-Lemeshow goodness-of-fit, variance inflation factor, tolerance, and condition index (Tolles and Meurer, 2016). When variables with >3 categories were found to fail the retention criterion or to have categories that did not differ significantly in their estimated OR, they were recoded into binary variables, which were then tested for inclusion. In the final best models, the OR that the dependent binary variable $= 1$ (“yes”) is given by the baseline OR (value of _cons) multiplied by the OR of each independent binary variable when they are $= 1$ (“yes”). Statistical analysis was performed using Stata, version 15.1 (StataCorp, College Station, TX).

Table 1

Practice demographics.

| Characteristic                      | Survey Distribution\(\text{n (\%)}\) |
|-------------------------------------|--------------------------------------|
| Years in practice \(n = 733\)       |                                       |
| ≤ 10                                | 330 (45.0)                           |
| 11–20                               | 205 (28.0)                           |
| > 20                                | 198 (27.0)                           |
| Location \(continent; n = 733\)     |                                       |
| Asia                                | 349 (47.6)                           |
| North America\(b\)                  | 137 (18.7)                           |
| Central/South America               | 131 (17.9)                           |
| Europe                              | 102 (13.9)                           |
| Other                               | 14 (1.9)                             |
| Population density of practice \(n = 733\) |                                     |
| Urban                               | 576 (78.6)                           |
| Suburban                            | 137 (18.7)                           |
| Rural                               | 20 (2.7)                             |
| Practice Setting \(n = 733\)        |                                       |
| Private                             | 346 (47.2)                           |
| Private and hospital                | 249 (34.0)                           |
| Tertiary hospital                   | 91 (12.4)                            |
| General hospital                    | 47 (6.4)                             |

\(a\) Percentages are rounded to the decimal place.

\(b\) Group includes predominantly U.S. participants.
Table 2
Practice specifics before and during the pandemic.

| Characteristic | Survey distribution \( \text{n} (\%) \) | Characteristic | Survey distribution \( \text{n} (\%) \) |
|----------------|---------------------------------|----------------|---------------------------------|
| **Activity** \( (n = 733) \) | | **Activity** \( (n = 733) \) | |
| Face-to-face consultations only | 542 (73.9) | Face-to-face consultations only | 68 (9.3) |
| TD consultations only | 0 (0) | TD consultations only | 277 (37.8) |
| Face-to-face and TD consultations | 191 (26.1) | Face-to-face and TD consultations | 274 (37.3) |
| Inactive | 0 (0) | Inactive | 114 (15.6) |
| **Patients seen per week** \( (n = 733) \) | | **Patients seen per week** \( (n = 288) \) | |
| \(<50\) | 109 (14.9) | \(<20\) | 180 (62.9) |
| 51–100 | 199 (27.2) | 21–40 | 73 (25.5) |
| 101–150 | 180 (24.6) | 41–60 | 14 (4.9) |
| 151–200 | 99 (13.5) | 61–80 | 10 (3.5) |
| 201–250 | 60 (8.2) | 80–100 | 6 (2.1) |
| \(>250\) | 86 (11.7) | \(>100\) | 3 (1.1) |
| **Procedures per week** \( (n = 733) \) | | **Performing procedures?** \( (n = 733) \) | |
| \(<20\) | 257 (35.1) | Yes | 188 (25.6) |
| 21–40 | 320 (43.7) | Type of procedure | |
| 41–60 | 94 (12.8) | Biopsy | 155 (82.4) |
| 61–80 | 33 (4.5) | Mohs surgery | 61 (32.4) |
| 81–100 | 16 (2.2) | Cryotherapy | 53 (28.2) |
| \(>100\) | 13 (1.8) | Electrosurgery | 53 (28.2) |
| | | Incision and drainage | 20 (10.6) |
| | | Excision | 19 (10.1) |

TD, teledermatology.

\( ^a \) Percentages are rounded to the decimal place.

Results

Descriptive data

Practice demographic characteristics are shown in Table 1.

Outcome data

Table 2 displays practice specifics before and during the pandemic. Table 3 shows data regarding TD use before and during the pandemic and in the future. Regarding pandemic conditions, 360 (49.1%), 197 (26.9%), and 176 (24.0%) participants reported \(<1000\), 1001 to 10,000, and 10,001 to 50,000 COVID-19 cases in their country, respectively. Furthermore, 486 participants (66.3%) responded that their area was in total lockdown whereas 246 participants (33.6%) were in partial lockdown.

Practice during the pandemic

Regarding the clinical activity of participants during the pandemic (Table 2), 37.8% of respondents provided only TD, 37.3% a combination of TD and in-person consultations, 9.3% solely in-person consultations, and 15.6% stopped clinical activity. Of those who stopped working, 79.8% were located in geographic locations on total lockdown \( (p < .001 \) for partial vs. total lockdown). More than one fourth of respondents were providing hospital services \( (27\% \text{ vs. } 52.8\% \text{ before the pandemic}; \ p < .001) \). The majority of participants \( (446 \text{ of } 773; 60.8\%) \) responded that outpatient dermatology clinics were discontinued at the hospital. Most participants who were providing hospital services \( (223 \text{ of } 287; 77.7\%) \) were seeing only emergencies at the hospital. The majority of participants \( (62.9\%) \) were consulting \(<20\) cases per week. Only 1.04% of respondents were consulting \(>100\) cases per week, compared with 58% before the pandemic \( (p < .001) \).

Only a quarter of respondents were performing procedures. Biopsy was the most common procedure, followed by micrographic (Mohs) surgery \( (82.4\% \text{ and } 32.4\%, \text{ respectively, of those performing procedures}) \). Excision was even less common \( (10.1\%)\),
and only 7.4% of participants performing procedures were doing cosmetic procedures. The median value for biopsies of suspicious pigmented lesions taken per week by dermatologists providing face-to face consultations during the pandemic (n = 220) was 1 (IQR, 0–3). The median value for biopsies postponed per week during the pandemic (n = 386) was 5 (IQR, 3–20). The mean values for biopsies taken (n = 88) and postponed (n = 94) in the North American group were 4.95 and 21.2, respectively.

Teledermatology
There was an almost 3-fold increase in the number of dermatologists practicing TD during compared with before the pandemic (75.2% vs. 26.1%; p < .001; Table 3). Only 6.8% of respondents were consulting >20 cases per week via TD before compared with 17.1% during the pandemic (p < .001). The percentage of respondents using TD for both follow-up and new patients increased from 37.2% before to 67% during the pandemic (p < .001). More than two thirds of participants (68.6%) expect to practice TD in the future, the majority (79.9%) as part of their regular practice. Respondents anticipated more consultations in the future than in the past (p < .001 for both), with North American respondents indicating the highest use.

The number of biopsies for suspicious pigmented lesions performed during the pandemic was associated with the number of patients seen per week before and during the pandemic, North American location, and the number of biopsies postponed per week (p < .001 for all). Practice location was associated with TD use during the pandemic and with its expected use in the future (p < .001 for both), with North American respondents indicating the highest use.

TD use during the pandemic showed a positive correlation with TD use before the pandemic, performing procedures, and more specifically with biopsies of suspicious pigmented lesions during the pandemic (p < .001 for each). Future TD use showed a positive

### Table 4

| Practice specifics during the pandemic | Patients/wk before the pandemic<sup>c</sup> | Patients/wk during the pandemic<sup>c</sup> | p-value<sup>b</sup> | Group analyses, n (%)<sup>a</sup> |
|---------------------------------------|------------------------------------------|------------------------------------------|----------------|---------------------------------|
| Patients/wk during the pandemic (n = 286) | Patients/wk before the pandemic<sup>c</sup> | < .001 | Y/GT: <10 (17.9); 11–20 (28.8); >20 (35.3) | <10 vs. 11–20 (p = .019) |
| Performing procedures during the pandemic (n = 733) | Years in practice | < .001 | Y/GT: NA (58.4); E (47.0); CSA (30.5); A (4.0) | <10 vs. 11–20 (p = .019) |
|  | Continent | < .001 | NA vs. CSA (p < .001); E vs. CSA (p < .009), CSA vs. A (p < .001) |
|  | Procedures/wk before the pandemic<sup>c</sup> | < .001 | NA vs. E (p = .009); NA vs. A (p = .001) |
| Incision and drainage (n = 188) | Continent | < .001 | Y/GT: A (42.8); E (12.5); NA (6.2); CSA (2.5) | A vs. NA (p < .001) |
| No. of biopsies of suspicious pigmented lesions per week (n = 188) | Continent | < .001<sup>f</sup> | NA Median (IQR), 2 (0–50) | A + CSA + E Median (IQR), 0 (0–20) |
|  | Patients/wk before the pandemic<sup>c</sup> | < .001<sup>f</sup> | >100 Median (IQR), 2 (0–50) | <100 Median (IQR), 0 (0–20) |
|  | Patients/wk during the pandemic<sup>c</sup> | < .001<sup>f</sup> | NA vs. E (p < .001); E vs. CSA (p < .001) |
|  | Number of biopsies postponed/wk | < .001<sup>f</sup> | NA vs. E (p = .009); E vs. CSA (p = .036) |
| TD use | TD use before the pandemic (n = 733) | Continent | < .001 | Y/GT: E (38.6); A (26.6); CSA (25.9); NA (16.7) |
|  | TD use during the pandemic (n = 733) | Continent | < .001 | Y/GT: NA (89.7); E (82.1); CSA (70.2); A (69.4) |
|  | TD use before the pandemic<sup>d</sup> | < .001 | NA vs. CSA (p < .001); E vs. CSA (p = .036) |
|  | Performing procedures during the pandemic<sup>d</sup> | < .001 | E vs. CSA (p = .022) |
|  | Taking biopsy during the pandemic<sup>d</sup> | < .001 | E vs. CSA (p = .022) |
| Future TD use (n = 733) | Continent | < .001 | Y/GT: NA (83.9); CSA (77.1); E (63.4); A (60.3) |
|  | Patients/wk before the pandemic<sup>c</sup> | < .001 | Y/GT: <100 (77.8); 101–200 (67.3); >200 (59.4) |
|  | TD use before the pandemic<sup>c</sup> | < .001 | Y/GT: Partial (76.8); total (64.4) |
|  | TD use during the pandemic<sup>c</sup> | < .001 | Y/GT: Partial (76.8); total (64.4) |
|  | Lockdown | < .001 | Y/GT: Partial (76.8); total (64.4) |

A, Asia; CSA, Central and South America; E, Europe; GT, group total; HIMG, hospital-issued management guidelines; IQR, interquartile range; NA, North America; TD, teledermatology; Y/GT, yes/group total.

<sup>a</sup> χ² test performed unless otherwise noted.
<sup>b</sup> Only statistically significant p-values are shown.
<sup>c</sup> Refers to the groups of variables in the second column.
<sup>d</sup> McNemar test.
<sup>e</sup> Percentage rounded to the decimal place. Percentages of groups are listed in descending order.
<sup>f</sup> Wilcoxon rank-sum (Mann Whitney) test.
<sup>g</sup> Spearman rank correlation.
correlation with the number of patients seen per week before the pandemic and with TD use before and during the pandemic ($p < .001$ for each).

Logistic regression models

The results from the logistic regression models are summarized in Table 5. TD use before the pandemic was the most powerful predictor of TD use during the pandemic (OR: 16.47; 95% confidence interval, 7.12–38.06; Table 5, Model 1). Other variables significantly contributing to the OR of TD use during the pandemic were North American practice location and continuing to perform procedures. The presence of >1000 COVID-19 cases in the respondent’s country had the largest effect on the OR of expecting future TD use (OR: 3.80; 95% confidence interval, 2.33–6.21; Table 5, Model 2). Other factors increasing this OR were TD use before the pandemic, using TD for both follow-up and new patients, and TD video visits during the pandemic.

Discussion

Impact on clinical activity

The COVID-19 pandemic is having a huge impact on dermatology practice, including a significant reduction in in-person consultations and nonemergency procedures, as well as a remarkable increase in TD use (Goldust et al., 2020b; Litchman and Rigel, 2020; Wollina, 2020). Our study confirms these trends by showing a 53% reduction in the number of dermatologists providing face-to-face consultations and a 49.1% increase in TD consultations. The survey also indicates that 15.6% of dermatologists stopped delivering care during the pandemic and were more likely to practice in areas of total rather than partial lockdown (Gorrepati and Smith, 2020).

Impact on procedures performed

Only one fourth of dermatologists continued performing procedures during the pandemic (Table 2). Biopsy was the most common, followed by Mohs surgery. Excision was performed less often than Mohs surgery, which possibly indicates a priority on treating high-risk tumors (i.e., performing Mohs surgery for high-risk squamous cell carcinoma while deferring treatment of low-risk tumors and deciding on a case-by-case basis for intermediate-risk tumors) per the current guidelines on management of patients with skin cancer during the pandemic (Baumann et al., 2020; British Association of Dermatologists and British Society for Dermatological Surgery, 2020; Geskin et al., 2020; National Comprehensive Cancer Network, 2020a). Cosmetic procedures were uncommon. Although this is due mainly to deferring elective procedures (Galadari et al., 2020), it might also indicate decreased patient interest in such treatments during the crisis (Guzman and Barbieri, 2020).

The number of biopsies for suspicious pigmented lesions per week (median: 1; IQR, 0–30) was associated with the number of patients seen per week both before and during the pandemic ($p < .001$ for both; Table 5). A median of five biopsies per week (IQR, 3–20) were postponed. Neither the numbers of biopsies per week performed nor those postponed were associated with TD use. The North American group had both a lower mean for biopsies taken (4.95) and a higher mean for biopsies postponed (21.2) compared with a U.S. group (7.7 and 10.7, respectively) in a study performed during the pandemic (Litchman and Rigel, 2020). This is possibly due to the data having been collected at an earlier stage in the pandemic (i.e., through the week of March 16 in the comparative study). The correlation between the numbers of biopsies for pigmented lesions performed and postponed may indicate that dermatologists have been focusing more on not missing a melanoma diagnosis than on keratinocytic carcinomas during this pandemic (Der Sarkissian et al., 2020; National Comprehensive Cancer Network, 2020b).

Impact on hospital service

COVID-19 has a considerable impact on dermatology care provided in the hospital setting (Chen et al., 2020). In this study, outpatient dermatology clinics were discontinued at the local hospital (60.8%), and the number of dermatologists providing hospital service decreased during compared with before the pandemic. This disruption is probably due to social distancing measures and concerns that dermatology examinations may be a vector of COVID-19 transmission (Cengiz et al., 2020; Kwatra et al., 2020). Our findings align with reports of dermatology specialty clinics being reduced or postponed indefinitely (Radi et al., 2020), and wards turned into COVID-19 care and quarantine centers in developing countries (Kumar et al., 2020).

Table 5

| Model | Dependent variable | Independent variables | LR $\chi^2$ | OR | SE | Z$^a$ | p-value | 95% CI |
|-------|-------------------|-----------------------|------------|----|----|-------|--------|--------|
| 1     | TD during the pandemic |             | 126.98    | 14.05 | 6.04 | 6.15 | .001 | 5.65–32.64 |
|       | TD before the pandemic |          |           | 2.99 | 0.96 | 3.43 | .001 | 1.60–5.60 |
|       | North America |             |           | 2.12 | 0.58 | 2.74 | .006 | 1.24–3.64 |
|       | Performing procedures during the pandemic |     | 1.77 | 0.35 | 2.93 | .003 | 1.21–2.60 |
|       | Future TD _cons$^b$ |             | 1.06 | 0.16 | 0.37 | .708 | 0.78–1.44 |
| 2     | Future TD use |             | 82.00    | 3.80 | 0.95 | 5.35 | .001 | 2.33–6.21 |
|       | >1000 COVID-19 cases in country |     | 2.51 | 0.66 | 3.51 | .001 | 1.50–4.21 |
|       | TD before the pandemic |          | 2.03 | 0.48 | 3.01 | .002 | 1.28–3.23 |
|       | TD during the pandemic: Both follow-up and new patients |   | 1.98 | 0.47 | 2.82 | .004 | 1.23–3.18 |
|       | TD type during the pandemic: Virtual (video) consultation _cons | | 0.55 | 0.13 | -2.58 | .009 | 0.35–0.86 |

CI, confidence interval; HIMG, hospital-issued management guidelines; LR, likelihood ratio; OR, odds ratio; PPE, personal protective equipment; SE, standard error; TD, teledermatology.

All LR $\chi^2 p < .0001$.

Numbers are rounded to two decimal places in all but the p-value column (three decimal places).

$^a$ $z$ defined as OR:SE.

$^b$ _cons estimates baseline odds.
Impact on teledermatology use

TD provides patients ongoing access to dermatologic care and affords a safer way to evaluate patients, including those with confirmed or suspected COVID-19 infection (Madigan et al., 2020). Our study showed a 49.1% increase in the number of participants providing TD consultations during the pandemic and a significantly increased number of participants using TD for both new and follow-up patients. Relaxed compliance with the Health Insurance Portability and Accountability Act of 1996 was allowed by state medical boards and other authorities, as indicated by 64.9% of our respondents. Similar initiatives taken by federal authorities could have enhanced the implementation of TD (Azar, 2020; Bressler et al., 2020). Furthermore, TD reimbursement improved during the pandemic, as evidenced by the fact that most states currently have parity laws that reimburse telehealth as a regular office visit whereas only 16 states had such laws before the pandemic (American Telemedicine Association, 2019). Recent advances in communication technology via modern video-conferencing equipment are facilitating telehealth. Innovations including real-time diagnostic data transfer and cloud technology are enhancing telehealth and making it more popular (Bhargava et al., 2020b).

The dramatic increase in TD use reflects a need to continue providing dermatology care for nonemergency cases and an expectation that TD can significantly reduce the risk of COVID-19 transmission (Gupta et al., 2020; Lee et al., 2020; Sheriff et al., 2020; Temiz et al., 2019). In this study, video visit was the most common type of TD during the pandemic, and the WhatsApp messenger was the most common platform used (Jakhar et al., 2020). This platform allows users to communicate via text/voice messages, photos, and videos. A recent report of WhatsApp use during the pandemic highlighted the strength of this platform and instant text messaging in health care providers’ activity (Duong et al., 2020). Despite a high percentage (42.3%) of nonreimbursement, more than two thirds of respondents (68.6%) expect to use TD in the future, the majority (68.6%) as part of their regular practice. Respondents anticipated more consultations in the future than during the pandemic.

Predictors of teledermatology use

Logistic regression analysis showed that TD use before the pandemic was the most powerful predictor of TD use during the pandemic, followed by North American practice location and performing procedures during the pandemic. The last association may indicate that providers who perform many procedures would prefer seeing medical dermatology cases and/or procedure follow-ups via TD. The factor with the largest increase in OR on the expectation of future TD use was >1000 COVID-19 cases in the participant’s country. This finding highlights the profound effect of the COVID-19 pandemic on future TD use.

Other factors in the logistic model that increased the OR for future TD use were TD use before the pandemic and TD use for both follow-up and new patients and video visits during the pandemic. Dermatologists who used TD for new patients during the pandemic could have accommodated more appointment requests using TD, and video TD consultations may offer an advantage in physician–patient interactions compared with other TD forms (e.g., phone call). T, which may explain why dermatologists who used TD for new patients and/or provided video TD consultations are more likely to plan to use TD in the future. Our finding aligns with reports of higher satisfaction for video than store-and-forward TD among dermatologists before the pandemic (Marchell et al., 2017; Mounessa et al., 2018).

Limitations

We had only a small number of respondents from Africa and Australia. Participants with lower patient volumes, especially in areas of total lockdown, may have had more time to respond. To minimize this bias, we sent reminder messages to invited participants on weekends. Recall biases cannot be excluded, but the large sample size and representative distribution possibly diminished these biases. No-response biases cannot be excluded, but access to social media and demographics did not differ between the groups of respondents and nonrespondents.

Conclusion

This global survey indicates a profound immediate effect of the COVID-19 pandemic on dermatology practices, including a decreased number of visits and nonessential procedures and a remarkable increase in TD use. The logistic regression models in our study suggest factors that might influence the OR for TD use during the pandemic and for the future. This pandemic appears to have substantially contributed to an increased use of TD in the long term.

Acknowledgments

The authors are thankful to Prof. Evangeline Handog and Dr. Mohammad Goldust for their assistance with the data collection.

Conflicts of Interest

None.

Funding

None.

Study Approval

N/A.

References

American Telemedicine Association. 2019 State of the States: Cover-age & reimbursement [Internet]. 2019 [cited 2020 August 10]. Available at: https://cdz2.hubspot.net/hubfs/5096139/Files/ Thought Leadership_ATA/2019 State of the States summary_final.pdf.
Azar AM II. Waiver or modification of requirements under Section 1335 of the Social Security Act [Internet]. 2020 [cited 2020 June 16]. Available at: https://www.phe.gov/emergency/news/healthactions/section1335/Pages/covid19-13March20.aspx.
Baumann BC, MacArthur KM, Brewer JD, Mendenhall W, Barker CA, Etzkorn JR, et al. Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer 2020;126(17):3900–6.
Bhargava S, Gupta M, Kroumpouzos G. Protection comes at a cost: Doctor’s life inside personal protection equipment. Dermatol Ther 2020 [Epub ahead of print].
Bhargava S, Negbenehoer N, Sadoughifar R, Ahmad S, Kroumpouzos G. Global impact on dermatology practice due to COVID-19. Clin Dermatol 2020 [Epub ahead of print].
Bhargava S, Rodke R, Rathod D, Kroumpouzos G. Employing dermatologists on the frontline against COVID-19: All hands on deck. Dermatol Ther 2020 [Epub ahead of print].
Bressler MV, Siegel DM, Markowitz O. Virtual dermatology: A COVID-19 update. Cutis 2020;105(4):163–4, E2.
British Association of Dermatologists and British Society for Dermatological Surgery. COVID-19 – Skin cancer surgery guidance. Clinical guidance for the management of skin cancer patients during the coronavirus pandemic [Internet]. 2020 [cited 2020 June 12]. Available at: http://www.bad.org.uk/ shared/get-file.aspx?itemtype=document&id=65685.
Cengiz FP, Emiroglu N, Bahali AG, Dizman D, Taslidere N, Akarslan TC, et al. Which dermatology patients attend to dermatology outpatient clinics during the SARS-
CoV-2 outbreak in Turkey and what happened to them? Dermatol Ther 2020 [Epub ahead of print].

Chen SY, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. J Thorac Dis 2017;9(6):1725–9.

Chen Y, Pradhan S, Xue S. What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus? J Am Acad Dermatol 2020;82(4):1034.

Der Sarkissian SA, Kim L, Veness M, Yiaseemides E, Sebaratnam DF. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol 2020;83(1):e29–30.

Duong TA, Veltcr C, Rybojad M, Conte C, Bagor M, Sulimovic L, et al. Did WhatsApp reveal a new cutaneous COVID-19 manifestation? J Eur Acad Dermatol Venereol 2020;34(8):e348–50.

Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med 2020;382(21):2049–55.

Fahmy DH, El-Amawy HS, El-Samongy MA, Fouda AA, Soliman SH, El-Kady A, et al. COVID-19 and dermatology: A comprehensive guide for dermatologists. J Eur Acad Dermatol Venereol 2020;34(7):1388–94.

Galadari H, Gupta A, Kroumpouzos G, Kassir M, Rudnicka L, Lotti T, et al. COVID-19 and its impact on cosmetic dermatology. Dermatol Ther 2020 [Epub ahead of print].

Giacone P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol 2020;34(6):1196–201.

Geskin LJ, Trager MH, Aasi SZ, Bickers DR, Carvajal RD, Nghiem P, et al. Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. J Am Acad Dermatol 2020;83(1):295–6.

Goldust M, Kroumpouzos G, Murrell D, Liu WL, Ackerman M. Patient and provider satisfaction with teledermatology. Telemed J E Health 2017;23(8):684–90.

Mounessa JS, Chapman S, Braunberger T, Qin R, Lipoff JB, Dellavalle RP, et al. A systematic review of satisfaction with teledermatology. J Telederm Telecare 2018;24(4):263–70.

Muddasani S, Housholder A, Fleischer AB. An assessment of United States dermatology practices during the COVID-19 outbreak. J Dermatol Treat 2020;31(5):436–8.

National Comprehensive Cancer Network. Advisory statement for non-melanoma skin cancer care during the COVID-19 pandemic [Internet]. 2020 [cited 2020 June 12]. Available at: https://www.nccn.org/covid-19/pdf/NCCN-NMSC.pdf.

National Comprehensive Cancer Network. Short-term recommendations for cutaneous melanoma management during COVID-19 pandemic [Internet]. 2020 [cited 2020 June 16]. Available at: https://www.nccn.org/covid-19/pdf/Melanoma.pdf.

Goldust M, Lotti T, von Stetten F, Murrell D. Teledermatology during the COVID-19 pandemic: Implications for patient demand for outpatient services and telehealth. J Am Acad Dermatol 2020;83(3):963–5.

Jahangir A, Koopman P, Murrell D. Dermatologists practice telemedicine during the COVID-19 pandemic: From bedside to phone-side. Clin Exp Dermatol 2020;45(6):739–40.

Kumar S, Bishini A, Vinay R. Changing paradigms of dermatology practice in developing nations in the shadow of COVID-19: Lessons learnt from the pandemic. Dermatol Ther 2020 [Epub ahead of print].

Kwatra SG, Sweren RJ, Grossberg AL. Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergency dermatology visits. J Am Acad Dermatol 2020;82(5):e179–80.

Lee I, Kovarik C, Tejasvi T, Pizarro M, Lipoff JB. Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol 2020;82(5):1213–4.

Litchman CH, Rigal DS. The immediate impact of COVID-19 on U.S. dermatology practices. J Am Acad Dermatol 2020;83(2):685–6.

Madigan LM, Michielliti RG, Shinkai K. How dermatologists can learn and contribute at the leading edge of the COVID-19 global pandemic. JAMA Dermatol 2020;156(7):733–4.

Mahmood S, Hasan K, Corder Carras M, Labrique A. Global preparedness against COVID-19: We must leverage the power of digital health. JMIR Public Health Surveill 2020;6(2):e18980.

Marchell R, Locatis C, Burgess G, Maisak R, Liu WL, Ackerman M. Patient and provider satisfaction with teledermatology. Telederm J E Health 2017;23(8):684–90.

Marchell R, Locatis C, Burgess G, Maisak R, Liu WL, Ackerman M. Patient and provider satisfaction with teledermatology. Telederm J E Health 2017;23(8):684–90.

Sheriff T, Murrell OG, Murrell DF. Restructuring an academic dermatology practice and its impact on cosmetic dermatology. Dermatol Ther 2020 [Epub ahead of print].

Sheriff T, Murrell OG, Murrell DF. Restructuring an academic dermatology practice and its impact on cosmetic dermatology. Dermatol Ther 2020 [Epub ahead of print].

Tarlo T, Singhal S, Murrell D, James WD. COVID-19 effects on dermatology specialty. Dermatol Ther 2020 [Epub ahead of print].

Tejada JA, Chen Y, Pradhan S, Xue S. Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol 2020;82(5):1213–4.

Tolles J, Meurer WJ. Logistic regression: Relating patient characteristics to the likelihood of requesting teledermatology consultations during the era of COVID-19. Dermatol Ther 2020 [Epub ahead of print].

Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: A useful tool to fight COVID-19. J Dermatol Treat 2020;31(4):e213–4.

Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: A useful tool to fight COVID-19. J Dermatol Treat 2020;31(4):e213–4.

Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: A useful tool to fight COVID-19. J Dermatol Treat 2020;31(4):e213–4.

Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther 2020 [Epub ahead of print].

Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther 2020 [Epub ahead of print].